Neurocrine Biosciences reported $4.6M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Abbvie ABBV:US $ 4021M 259M
Acadia Pharmaceuticals ACAD:US $ 2.95M 0.39M
Acorda Therapeutics ACOR:US $ 5.97M 1.77M
ALKERMES ALKS:US 55.16M 1.48M
Alnylam Pharmaceuticals ALNY:US $ 35.63M 2.04M
Amgen AMGN:US $ 1561M 157M
Biogen BIIB:US $ 753.9M 93.8M
Biomarin Pharmaceutical BMRN:US $ 116.96M 2.78M
Dynavax Technologies DVAX:US $ 39.96M 34.05M
Exelixis EXEL:US $ 13.2M 0.29M
Gilead Sciences GILD:US $ 1424M 1203M
Halozyme Therapeutics HALO:US $ 15.92M 5.66M
Intercept Pharmaceuticals ICPT:US $ 0.76M 0.26M
Intra Cellular Therapies ITCI:US $ 3.16M 0.62M
IONIS PHARMACEUT IONS:US $ 4.17M 1.94M
Nektar Therapeutics NKTR:US $ 5.32M 0.85M
Neurocrine Biosciences NBIX:US $ 4.6M 0.5M
Pfizer PFE:US $ 10010M 399M
Regeneron Pharmaceuticals REGN:US $ 404.9M 577.7M
Repligen RGEN:US $ 82.36M 0.31M
Rigel Pharmaceuticals RIGL:US $ 0.12M 0.37M
Sarepta Therapeutics SRPT:US $ 31.44M 0.3M
Teva Pharmaceutical TEVA:IT 1.86B 116M
Ultragenyx Pharmaceutical RARE:US $ 6.1M 2.59M
Vertex Pharmaceuticals VRTX:US $ 245.8M 1.59M
YTE INCY:US $ 37.21M 1.36M